How much does Infliximab typically cost?
Infliximab, also known as Remicade, is a biologic medication used to treat various autoimmune diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease. The cost of Infliximab can vary depending on several factors, including the country, region, insurance coverage, and treatment duration.
According to a recent report by PharmacyTimes, the list price of Infliximab in the United States can range from $4,000 to $6,000 per vial, with a typical course of treatment consisting of 4-6 vials. However, with discounts and rebates, the net price paid by patients and payers can be significantly lower.
[1] As reported by PharmacyTimes, a study published in the Journal of Managed Care & Specialty Pharmacy found that the average wholesale price of Infliximab in the US was around $5,200 per vial in 2022. However, after applying discounts and rebates, the average net price paid by patients and payers was around $1,500 per vial.
How do prices compare internationally?
Infliximab prices can vary significantly across different countries. A report by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) found that the average price of Infliximab in Europe was around $2,500 per vial in 2022, compared to around $5,200 in the US.
[2] The IFPMA report noted that prices for Infliximab in Europe were influenced by the European Union's (EU) pricing policies, which aim to ensure that patients have access to affordable medicines. The report also highlighted that prices for Infliximab can vary significantly between EU countries.
Do biosimilars offer a more affordable alternative?
Biosimilars, or follow-on biologics, are versions of existing biologic medications that have been approved by regulatory authorities. Biosimilar versions of Infliximab, such as Infliximab-abda (Renflexis) and Infliximab-dyyb (Inflectra), have been approved in several countries, including the US and EU.
[3] As reported by Statista, the prices of biosimilar Infliximab products can be significantly lower than those of the originator product. In the US, for example, the list price of Renflexis was around $3,200 per vial in 2022, compared to around $5,200 for the originator product.
However, it's essential to note that the availability and pricing of biosimilars can vary depending on the country and region.
Sources:
[1] PharmacyTimes: Study Finds Infliximab Prices Vary Widely in US (2022)
[2] IFPMA: Pharmaceutical Pricing and Affordability in Europe (2022)
[3] Statista: Biosimilar infliximab products - List prices worldwide 2022
Please note that prices and availability of medications can change over time, and this information may not reflect the current situation.